What were Supriya Lifescience Ltd's latest quarterly results?
Supriya Lifescience Ltd's latest quarterly results (Dec 2025) show
- PAT Growth YoY: +6.4% (stable)
- Revenue Growth YoY: +10.8%
- Operating Margin: 35.0% (contracting)
Supriya Lifescience Ltd: Why Is It Outperforming Nifty 500?
ActiveWeakNew This Week
In , Supriya Lifescience Ltd (Pharma - API & CRAMS) is outperforming Nifty 500 with +7.0% relative strength. Fundamentals: Weak.
Supriya Lifescience Ltd Key Facts
- PE Ratio
- 30.6x
- Market Cap
- ₹5,688 Cr
- PAT Growth YoY
- +6%
- Revenue Growth YoY
- +11%
- OPM
- 35.0%
- RS vs Nifty 500
- +7.0%
PE: Near PeakStrong Opportunity
What's Happening
💎PE falling while earnings hold — value emerging
🏦Virtually debt-free company
🌐FII stake decreased 0.6% this quarter
Key Numbers
PAT Growth YoY
+6%
Stable
Revenue YoY
+11%
Stable
Operating Margin
35.0%
-100 bps YoY
PE Ratio
30.6
Current Price
₹707
Dividend Yield
0.14%
Fundamental Score
35/100
Weak
3Y PAT CAGR
+7%
Market Cap
5.7K Cr
Valuation
N/A12-Week Performance
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
12 weeks agoThis week
How Fast Is Supriya Lifescience Ltd Growing?
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +11% | +10% | Stable |
| PAT (Net Profit) | +6% | +7% | Stable |
| OPM | 35.0% | -100 bps | Contracting |
Other Top Pharma - API & CRAMS Stocks Beating Nifty 500
Frequently Asked Questions: Supriya Lifescience Ltd
Based on publicly available financial data. This is educational research, not investment advice.
Is Supriya Lifescience Ltd's profit growing or declining?
Supriya Lifescience Ltd's profit is growing with an stable trend.
- PAT Growth YoY: +6.4% (latest quarter)
- PAT Growth QoQ: 0.0% (sequential)
- 3-Year PAT CAGR: +7.3%
- Trend: Stable — consistent growth pattern
What is Supriya Lifescience Ltd's revenue growth trend?
Supriya Lifescience Ltd's revenue growth trend is stable.
- Revenue Growth YoY: +10.8%
- Revenue Growth QoQ: +3.0% (sequential)
- 3-Year Revenue CAGR: +9.5%
How is Supriya Lifescience Ltd's operating margin trending?
Supriya Lifescience Ltd's operating margin is contracting.
- Current OPM: 35.0%
- OPM Change YoY: -1.0% basis points
- OPM Change QoQ: -1.0% basis points
What is Supriya Lifescience Ltd's 3-year profit and revenue CAGR?
Supriya Lifescience Ltd's long-term compounding rates
- 3-Year Profit CAGR: +7.3%
- 3-Year Revenue CAGR: +9.5%
Is Supriya Lifescience Ltd's growth accelerating or decelerating?
Supriya Lifescience Ltd's earnings growth is stable with mixed signals on a sequential basis.
- YoY Acceleration: -2.3% bps
- Sequential Acceleration: -42.9% bps
- Margin Warning: Operating margins are under pressure
What is Supriya Lifescience Ltd's trailing twelve month (TTM) performance?
Supriya Lifescience Ltd's trailing twelve month (TTM) performance
- TTM PAT: ₹185 Cr
- TTM PAT Growth: +5.7% YoY
- TTM Revenue: ₹735 Cr
- TTM Revenue Growth: +9.5% YoY
- TTM Operating Margin: 36.0%
What is Supriya Lifescience Ltd's current PE ratio?
Supriya Lifescience Ltd's current PE ratio is 30.6x.
- Current PE: 30.6x
- Market Cap: 5.7K Cr
- Dividend Yield: 0.14%
What is Supriya Lifescience Ltd's price-to-book ratio?
Supriya Lifescience Ltd's price-to-book ratio is 5.3x.
- Price-to-Book (P/B): 5.3x
- Book Value per Share: ₹134
- Current Price: ₹707
Is Supriya Lifescience Ltd a fundamentally strong company?
Supriya Lifescience Ltd is rated Weak with a fundamental score of 34.76/100. This score is calculated from objective financial metrics
- Revenue Growth YoY: +10.8% (10% weight)
- PAT Growth YoY: +6.4% (10% weight)
- PAT Growth QoQ: 0.0% (10% weight)
- Margins contracting (10% weight)
Is Supriya Lifescience Ltd debt free?
Supriya Lifescience Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹5 Cr
What is Supriya Lifescience Ltd's return on equity (ROE) and ROCE?
Supriya Lifescience Ltd's return ratios over recent years
- FY2023: ROCE 19.0%
- FY2024: ROCE 22.0%
- FY2025: ROCE 27.0%
Is Supriya Lifescience Ltd's cash flow positive?
Supriya Lifescience Ltd's operating cash flow is positive (FY2025).
- Cash from Operations (CFO): ₹165 Cr
- Free Cash Flow (FCF): ₹13 Cr
- CFO/PAT Ratio: 88% (strong cash conversion)
What is Supriya Lifescience Ltd's dividend yield?
Supriya Lifescience Ltd's current dividend yield is 0.14%.
- Dividend Yield: 0.14%
- Current Price: ₹707
Who holds Supriya Lifescience Ltd shares — promoters, FII, DII?
Supriya Lifescience Ltd's shareholding pattern (Mar 2026)
- Promoters: 68.3%
- FII (Foreign): 5.2%
- DII (Domestic): 5.7%
- Public: 20.8%
Is promoter holding increasing or decreasing in Supriya Lifescience Ltd?
Supriya Lifescience Ltd's promoter holding has remained stable recently.
- Current Promoter Holding: 68.3% (Mar 2026)
- Previous Quarter: 68.3% (Dec 2025)
- Change: 0.00% (stable)
How long has Supriya Lifescience Ltd been outperforming Nifty 500?
Supriya Lifescience Ltd has been outperforming Nifty 500 for 1 consecutive week, indicating early-stage outperformance.
Is Supriya Lifescience Ltd a new momentum entry or an established outperformer?
Supriya Lifescience Ltd is a new entry this week — it just started outperforming Nifty 500. New entries are worth monitoring for follow-through.
Is Supriya Lifescience Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Supriya Lifescience Ltd may be worth studying
- Earnings growing at +6.4% YoY
- Cash flow is positive — CFO ₹165 Cr
What is the investment thesis for Supriya Lifescience Ltd?
Supriya Lifescience Ltd investment thesis summary:
Research Signals (Bull Case)
- Revenue growing at +10.8% YoY
Risk Factors (Bear Case)
- Margins under pressure
What is the future outlook for Supriya Lifescience Ltd?
Supriya Lifescience Ltd's forward outlook based on current data signals
- Earnings Trend: stable
- Revenue Trend: stable
- Margin Trend: contracting
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.